5.22
-0.06 (-1.14%)
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Bearish | Bearish |
Biotechnology (Global) | Bearish | Bearish | |
Stock | Omeros Corporation | - | - |
Stockmoo Score
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy. |
|
Sector | Healthcare |
Industry | Biotechnology |
Investment Style | Small Value |
Ownership
Name | Date | Shares Held |
---|---|---|
Ingalls & Snyder Llc | 31 Mar 2024 | 4,698,140 |
Stifel Financial Corp | 31 Mar 2024 | 1,909,129 |
Corient Private Wealth Llc | 31 Mar 2024 | 623,663 |
Nomura Holdings Inc | 31 Mar 2024 | 450,829 |
No data within this time range.
No data within this time range.
Date | Type | Details |
---|---|---|
04 Jun 2024 | Announcement | Omeros Announces Webcast Details for Annual Meeting of Shareholders |
03 Jun 2024 | Announcement | Omeros Corporation Further Strengthens its Balance Sheet through Series of Financing Transactions Extending Maturity on a Majority of its Outstanding Debt into 2028 |
15 May 2024 | Announcement | Omeros Corporation Reports First Quarter 2024 Financial Results |
10 May 2024 | Announcement | Omeros Corporation to Announce First Quarter Financial Results on May 15, 2024 |
09 May 2024 | Announcement | Omeros Corporation Announces Upcoming Presentations at 2024 European Hematology Association (EHA) Hybrid Congress |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2024 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |